Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Dicerna Pharmaceuticals	Prestige Consumer Healthcare	Zentalis Pharmaceuticals	Arcus Biosciences	Cryoport
Symbol	NASDAQ:DRNA	NYSE:PBH	NASDAQ:ZNTL	NYSE:RCUS	NASDAQ:CYRX
Price Information
Current Price	$25.93	$48.83	$55.69	$28.09	$48.42
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	2.0	1.6	1.4	1.7	1.7
Analysis Score	4.5	3.3	1.5	3.5	3.5
Community Score	3.0	2.8	3.3	2.5	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	1.7	1.7	1.7
Earnings & Valuation Score	0.6	1.9	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$42.29	$89.60	$62.60	$51.50	$72.57
% Upside from Price Target	63.08% upside	83.49% upside	12.41% upside	83.34% upside	49.88% upside
Trade Information
Market Cap	$2.02 billion	$2.42 billion	$2.43 billion	$2.02 billion	$2.28 billion
Beta	1.33	0.76	N/A	1.26	1.23
Average Volume	793,897	490,598	297,746	531,825	593,023
Sales & Book Value
Annual Revenue	$23.90 million	$963.01 million	N/A	$15 million	$33.94 million
Price / Sales	83.43	2.53	N/A	132.95	65.17
Cashflow	N/A	$4.75 per share	N/A	N/A	N/A
Price / Cash	N/A	10.29	N/A	N/A	N/A
Book Value	$2.22 per share	$23.30 per share	N/A	$3.57 per share	$3.52 per share
Price / Book	11.68	2.10	N/A	7.87	13.76
Profitability
Net Income	$-120,460,000.00	$142.28 million	N/A	$-84,710,000.00	$-18,330,000.00
EPS	($1.76)	$2.96	N/A	($1.93)	($0.55)
Trailing P/E Ratio	N/A	15.16	0.00	N/A	N/A
Forward P/E Ratio	N/A	14.89	N/A	N/A	4,842.00
P/E Growth	N/A	2.96	N/A	N/A	N/A
Net Margins	-88.81%	17.03%	N/A	-112.63%	-55.87%
Return on Equity (ROE)	-71.72%	13.76%	N/A	-27.43%	-17.68%
Return on Assets (ROA)	-16.60%	4.80%	N/A	-20.96%	-11.32%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	1.22%	N/A	N/A	0.93%
Current Ratio	2.62%	1.98%	N/A	4.89%	16.13%
Quick Ratio	2.62%	1.14%	N/A	4.89%	16.09%
Ownership Information
Institutional Ownership Percentage	80.64%	N/A	67.13%	60.56%	88.29%
Insider Ownership Percentage	11.30%	1.20%	N/A	19.71%	11.50%
Miscellaneous
Employees	302	520	124	236	605
Shares Outstanding	76.90 million	49.91 million	41.31 million	71.00 million	45.68 million
Next Earnings Date	8/5/2021 (Estimated)	8/5/2021 (Estimated)	5/21/2021 (Estimated)	8/5/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Cryoport, Inc. (NASDAQ:CYRX) Expected to Post Earnings of -$0.13 Per Share americanbankingnews.com - May 16 at 4:06 PM
	CryoPort (CYRX) Stock Returns: Average and Excess Return for CYRX after a Fall or Rise - AI Dashboard - Trefis dashboards.trefis.com - May 14 at 1:59 PM
	Notable Two Hundred Day Moving Average Cross - CYRX nasdaq.com - May 13 at 12:07 AM
	Needham & Company LLC Boosts Cryoport (NASDAQ:CYRX) Price Target to $77.00 marketbeat.com - May 11 at 8:41 AM
	Needham & Company LLC Raises Cryoport (NASDAQ:CYRX) Price Target to $77.00 americanbankingnews.com - May 11 at 8:37 AM
	Cryoport (NASDAQ:CYRX) Trading Down 9.8% americanbankingnews.com - May 10 at 5:42 PM
	Leerink Partners Stick to Their Buy Rating for CryoPort Inc investing.com - May 10 at 9:53 AM
	Form 4 Cryoport, Inc. For: Apr 30 Filed by: ZECCHINI EDWARD J - StreetInsider.com streetinsider.com - May 7 at 11:39 PM
	Cryoport (NASDAQ:CYRX) Rating Increased to Hold at Zacks Investment Research marketbeat.com - May 7 at 8:15 PM
	Q2 2021 Earnings Estimate for Cryoport, Inc. (NASDAQ:CYRX) Issued By SVB Leerink americanbankingnews.com - May 7 at 7:46 AM
	LabConnect, Cryoport Partner To Support Triumvira Trial Logistics - Contract Pharma contractpharma.com - May 7 at 12:16 AM
	Cryoport sees revenue jump more than 445% during first quarter - Nashville Business Journal - Nashville Business Journal bizjournals.com - May 6 at 7:16 PM
	LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - Murfreesboro Post murfreesboropost.com - May 6 at 2:15 PM
	LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - PRNewswire prnewswire.com - May 6 at 8:38 AM
	LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial finance.yahoo.com - May 6 at 8:38 AM
	Cryoport Inc. (NASDAQ:CYRX) stock surged in the current trading session; here’s why - Market Globalist marketglobalist.com - May 5 at 5:37 PM
	What is the Market's View on CryoPort Inc (CYRX) Stock's Price and Volume Trends Wednesday? - InvestorsObserver investorsobserver.com - May 5 at 5:37 PM
	Cryoport grows revenue 445% \| Area Stocks \| nashvillepost.com - Nashville Post nashvillepost.com - May 5 at 5:37 PM
	Cryoport (NASDAQ:CYRX) PT Raised to $77.00 americanbankingnews.com - May 5 at 3:27 PM
	Cryoport (NASDAQ:CYRX) Shares Gap Up on Strong Earnings americanbankingnews.com - May 5 at 11:10 AM
	Cryoport (NASDAQ:CYRX) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS americanbankingnews.com - May 4 at 11:30 PM
	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq nasdaq.com - May 4 at 11:17 PM
	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 4 at 11:17 PM
	CryoPort Stock Is Estimated To Be Modestly Undervalued - Yahoo Finance finance.yahoo.com - May 4 at 6:17 PM
	Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 - PRNewswire prnewswire.com - May 4 at 6:17 PM
	Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 finance.yahoo.com - May 4 at 6:16 PM
	CryoPort Q1 2021 Earnings Preview - Seeking Alpha seekingalpha.com - May 3 at 7:56 PM

Date	Company	Brokerage	Action
4/22/2021	Dicerna Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage
4/19/2021	Dicerna Pharmaceuticals	Truist Securities	Boost Price Target
4/13/2021	Dicerna Pharmaceuticals	SVB Leerink	Lower Price Target
3/8/2021	Dicerna Pharmaceuticals	Chardan Capital	Boost Price Target
3/8/2021	Dicerna Pharmaceuticals	HC Wainwright	Boost Price Target
3/1/2021	Dicerna Pharmaceuticals	B. Riley	Boost Price Target
5/12/2020	Dicerna Pharmaceuticals	Royal Bank of Canada	Initiated Coverage
5/11/2020	Dicerna Pharmaceuticals	SunTrust Banks	Boost Price Target
5/17/2021	Prestige Consumer Healthcare	DA Davidson	Boost Price Target
12/2/2020	Prestige Consumer Healthcare	BMO Capital Markets	Upgrade
11/9/2020	Prestige Consumer Healthcare	CIBC	Boost Price Target
11/6/2020	Prestige Consumer Healthcare	TD Securities	Boost Price Target
6/29/2020	Prestige Consumer Healthcare	Sidoti	Upgrade
6/17/2020	Prestige Consumer Healthcare	Oppenheimer	Reiterated Rating
4/14/2020	Prestige Consumer Healthcare	Jefferies Financial Group	Downgrade
1/19/2021	Zentalis Pharmaceuticals	Wedbush	Initiated Coverage
12/16/2020	Zentalis Pharmaceuticals	Morgan Stanley	Boost Price Target
9/28/2020	Zentalis Pharmaceuticals	Cantor Fitzgerald	Initiated Coverage
4/28/2020	Zentalis Pharmaceuticals	Guggenheim	Initiated Coverage
2/25/2021	Arcus Biosciences	Barclays	Boost Price Target
2/25/2021	Arcus Biosciences	Mizuho	Boost Price Target
1/20/2021	Arcus Biosciences	Benchmark	Boost Price Target
11/24/2020	Arcus Biosciences	Berenberg Bank	Initiated Coverage
11/23/2020	Arcus Biosciences	Evercore ISI	Initiated Coverage
6/2/2020	Arcus Biosciences	Citigroup	Boost Price Target
4/16/2020	Arcus Biosciences	BTIG Research	Boost Price Target
5/11/2021	Cryoport	Needham & Company LLC	Boost Price Target
3/22/2021	Cryoport	UBS Group	Initiated Coverage
1/19/2021	Cryoport	KeyCorp	Boost Price Target
1/14/2021	Cryoport	Roth Capital	Boost Price Target
8/24/2020	Cryoport	Stephens	Boost Price Target

(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources